Skip Navigation

JNCI Journal of the National Cancer Institute 1999 91(24):2075-2077; doi:10.1093/jnci/91.24.2075
© 1999 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Volkers, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Volkers, N.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 91, No. 24, 2075-2077, December 15, 1999
© 1999 Oxford University Press

NEWS

ASTRO Plenary Session Touts Top New Research

Nancy Volkers

High-dose radiation is a catch-22 in cancer treatment: It's effective at killing cancer cells but extremely dangerous to normal tissues. Recent research shows that in certain men with prostate cancer, the benefits seem to exceed the costs.

According to Alan Pollack, M.D., Ph.D., of the University of Texas M. D. Anderson Cancer Center, Houston, prostate cancer patients whose pretreatment prostate-specific antigen levels are above 10 have less recurrence and fewer distant metastases when treated with high-dose radiation, compared with standard doses of . . . [Full Text of this Article]

Hormone Edge


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?